[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412641":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":26,"locations":35,"responsibleParty":62,"collaborators":64,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":26,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":26,"overallStatus":88,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Chelsea and Westminster NHS Foundation Trust","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Biktarvy treatment","EXPERIMENTAL","First-line HIV treatment of Biktarvy OD for 48 weeks",[13],"Drug: Biktarvy",{"label":15,"type":16,"description":17,"interventionNames":18},"Symtuza treatment","ACTIVE_COMPARATOR","First-line HIV treatment of Symtuza OD for 48 weeks",[19],"Drug: Symtuza",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Biktarvy","Combination single tablet anti-retroviral therapy: bictegravir 50mg\u002Femtricitabine 200mg\u002Ftenofovir alafenamide 25mg",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Symtuza","Combination single tablet anti-retroviral therapy: darunavir 800mg\u002Fcobicistat 150mg\u002Femtricitabine 200mg\u002Ftenofovir alafenamide 10mg",[15],[32],{"name":33,"affiliation":5,"role":34},"Marta Boffito, MD PhD FRCP","PRINCIPAL_INVESTIGATOR",[36,48,57],{"facility":37,"status":26,"city":38,"state":26,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":26},"Brighton and Sussex University Hospitals NHS Trust Lawson Unit Royal Sussex County Hospital","Brighton","BN2 5BE","United Kingdom","UK",{"type":43,"coordinates":44},"Point",[45,46],-0.13947,50.82838,{"lat":46,"lon":45},{"facility":49,"status":26,"city":50,"state":26,"zip":51,"country":40,"countryCode":41,"cosmosGeoPoint":52,"geoPoint":56,"contacts":26},"Chelsea and Westminster Hospital NHS Foundation Trust","London","SW10 9NH",{"type":43,"coordinates":53},[54,55],-0.12574,51.50853,{"lat":55,"lon":54},{"facility":58,"status":26,"city":50,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":59,"geoPoint":61,"contacts":26},"Imperial College Healthcare NHS Trust",{"type":43,"coordinates":60},[54,55],{"lat":55,"lon":54},{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[65,67],{"name":66,"class":6},"Imperial College London",{"name":68,"class":69},"Gilead Sciences","INDUSTRY","100412641","phase-3-efficacy-of-bicftaf-versus-standard-of-care-in-the-treatment-of-new-hiv-infection-diagnoses-in-the-context-of-test-and-treat-100412641",false,"NCT04653194","Efficacy of BIC\u002FF\u002FTAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'","BIC-T&T","Inclusion Criteria:\n\n1. Is male or female aged 18 years or over.\n2. Confirmed diagnosis of HIV-1 as per local clinic definition less than 14 days before day treatment is to be initiated.\n3. Is capable of giving informed consent.\n4. Is willing to comply with the protocol requirements\n5. A female may be eligible to enter and participate in the study if she:\n\n   1. is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,\n   2. is of child-bearing potential with a negative pregnancy test at Screening (\\& baseline visit) and agrees to use one of the methods of contraception to avoid pregnancy indicated in Appendix 4 during the study and for a period of 12 weeks after the study.\n6. Men who have partners who are women of childbearing potential (WOCBP - definition in Appendix 4) must be using an adequate method of contraception as listed in Appendix 4 to avoid pregnancy in their partner throughout the study and for a period of at least 12 weeks after the study;\n\nExclusion Criteria:\n\n1. Infected by HIV-2\n2. On PEP\n3. Use of medications that are know to interact with either treatment B or S\n4. Unstable health conditions that according to the opinion of the Investigator suggest the individual should not take part in the trial (including unstable liver diseases, possible opportunistic infections, etc)\n5. Women planning pregnancy or who are pregnant or breast feeding. (NB: See section 4.4; Withdrawal Criteria and Section 10.4; Collection and Follow up of Adverse Events if pregnancy does occur in a trial subject)\n6. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomisation.\n7. Known acute or chronic viral hepatitis including, but not limited to, A, B, or C\n8. Any investigational drug within 30 days prior to the trial drug administration\n9. Any other condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.","ALL","18 Years",{"count":80,"type":81},36,"ACTUAL","INTERVENTIONAL",[84],"PHASE3","The administration of combination antiretroviral therapy (cART) to HIV-infected patients has been associated with a dramatic reduction in AIDS-related morbidity and mortality. Time to cART start is currently approximately 2-4 weeks after diagnosis, mostly deferred for reasons of waiting for baseline blood test results; in particular HIV genotype, CD4 count, OI screen and logistics of a consultant clinical review. Whilst there is a clear rationale for this delay there is a risk of loss to follow-up as well as the potential risk of onward viral transmission. The balance between \"readiness\" to start ART against pragmatic and practical safe initiation of treatment needs to be tested using currently available safe potent antiretroviral agents in a head-to-head comparison study to allow careful rigorous comparisons of outcomes.\n\nThis study will recruit 36 newly diagnosed HIV patients to be started on treatment immediately upon diagnosis. This would optimally be within 7 days, for eligibility to the study up to 14 days will be permissible. Patients will be randomised to one of two open-label combination therapies known to be highly effective; Biktarvy or Symtuza. The patients will receive study treatment for 48 weeks. The two therapies will be compared by the change in HIV viral load from start of treatment to 12 weeks. Further clinical data will be recorded for the trial patients and exploratory investigations undertaken. As those recruited to the trial may not be representative of the full cohort of newly diagnosed HIV patients there will also be data collected on all newly diagnosed patients in a given period. This data will contribute to conclusions on the benefits and issues of implementing test and treat.",[87],"Human Immunodeficiency Virus","COMPLETED","2024-02-07",{"date":91,"type":81},"2024-02-08",{"date":93,"type":81},"2020-09-30",{"date":95,"type":81},"2023-07-31",{"name":5,"class":6},3]